Researchers have identified a molecular signal in blood that could help detect the earliest warning signs of ovarian cancer, potentially opening a new direction for diagnosing a disease that is often discovered at an advanced stage.
The findings, published in the journal Nature Medicine on November 10, 2026, focus on an RNA molecule called Tu-Stroma. Scientists found that measuring its levels in blood samples could help identify microscopic precancerous changes linked to ovarian cancer.
Understanding the Early Signs of Ovarian Cancer
Ovarian cancer, particularly high-grade serous carcinoma, can begin with abnormal cellular changes in the lining of the fallopian tubes. These changes are known as serous tubal intraepithelial carcinoma (STIC).
Because these lesions are microscopic, they can remain difficult to identify through conventional imaging and existing screening methods. Researchers therefore investigated whether a molecular signal released into the bloodstream could reveal these changes earlier.
How the New Blood Test Works
The research team studied Tu-Stroma, a tumour-associated RNA molecule found in small particles circulating in the blood. They examined blood samples from individuals with normal tissue, benign conditions, STIC and different stages of ovarian cancer.
The study reported that the marker was elevated in women with STIC and high-grade serous ovarian cancer. This suggests that the blood-based approach could potentially identify biological changes before an invasive tumour becomes detectable through conventional methods.
Promising Accuracy in Research Findings
In a validation group, the test detected STIC in 92.3% of affected women and correctly identified 98.2% of healthy women.
Researchers also assessed how the test might perform among women with inherited risk factors for ovarian cancer. Their modelling suggested that around 72% of positive results could be accurate, while negative results would be correct nearly 100% of the time in that particular high-risk setting.
These findings are encouraging, although further research is needed to establish how reliably the test performs in wider populations.
Potential Importance for Women at High Risk
Women with inherited genetic risk factors sometimes face difficult decisions about preventive surgery involving the removal of their fallopian tubes and ovaries.
At present, such decisions are often guided by genetic risk and medical history. A test capable of identifying precancerous changes could eventually provide additional biological information to help doctors and patients assess their options.
However, the researchers have not established that the test can independently determine whether preventive surgery is necessary.
More Research Needed Before Clinical Use
The findings represent an important research development, but the blood test is not yet an established routine screening tool for ovarian cancer.
Researchers will need to conduct prospective studies involving larger groups of women and follow participants over time. These studies will help determine how early the marker appears, how accurately it identifies precancerous changes and whether using it improves clinical decisions.
A New Direction in Cancer Detection
The discovery shifts attention from finding small tumours to identifying molecular changes that may occur before invasive cancer develops. If further studies confirm its effectiveness, the approach could eventually contribute to more personalised ovarian cancer monitoring, particularly for women at higher risk.
For now, scientists see Tu-Stroma as a promising research marker rather than a confirmed replacement for existing medical assessments.







